<DOC>
	<DOCNO>NCT01212354</DOCNO>
	<brief_summary>The major clinical problem predominant cause death radio-oncological treatment H+N cancer loco-regional relapse . This randomized trial test hypothesis dose escalate Intensity Modulated Radiotherapy ( IMRT ) selectively apply macroscopic primary tumor involve neck node - 80 % - hypoxic improve loco-regional control least 15 % 2 year . IMRT combine concurrent Cis-Platin chemotherapy . Tumor volume correlate number malignant cell well tumor hypoxia important biological parameter increase radio-resistance , failure local control tumor progression . Basing data experimental clinical radiation oncology consider hypoxia useful parameter pre-therapeutic strati-fication future randomize radio-chemotherapy trial . In addition , hypoxia image PET use test significance selective dose escalation hypoxic tumor sub-volumes ( `` Dose Painting '' ) . As prerequisite innovative study address hypoxia translational part investigate follow key issue : correlation size total tumor volume ( primary , lymph node ) hypoxic sub-volume , spatial shift hypoxic sub-volume start treatment correlation loco-regional control hypoxia . Before start main study pre-study ass occurrence radiation induce toxicity mandatory perform . In step-wise dose-escalation cohort-design safety dose-escalation determine . Step one : 6 patient Step two : 14 patient . In pre-study 1st group ( 6 patient ) treat 2.2 Gy 77.0 Gy DEVPT DEVLK . After evaluation toxicity next 14 patient treated scheme .</brief_summary>
	<brief_title>Impact Selective Radiation Dose Escalation Tumour Hypoxia Status Locoregional Tumour Control After Radiochemotherapy HNT</brief_title>
	<detailed_description>The pre-study sequential design prospective multicentre interventional pilot study assess toxicity intensity modulate radiotherapy ( IMRT ) plus Cisplatin head neck cancer The main study multicenter phase III randomize trial effect dose escalate radiotherapy concomitant chemotherapy treat local advance head neck cancer . The study compare two treatment arm : Experimental intervention ( group A ) : 7 week standard radio-chemotherapy 20 mg/m²/d Cisplatin week 1 5 include simultaneous radiation dose escalation ( 5x2.3 Gy per week 80.5 Gy total dose ) primary tumour involve neck node ≥ 2 cm . The Dose Escalated tumour Volume ( DEVPT ) define macroscopic ( Gross ) primary Tumour Volume ( GTVPT ) minus 3 mm margin organ risk mucosal site reduce risk high dose deposition surround normal tissue . All involved lymph node visualize CT minimal diameter 2 cm also include dose escalation ( DEVLN ) . The DEVLN lymph node &gt; 2 cm determine involved lymph node volume ( GTVLN ) minus margin 3 mm organ risk mucosal site . The 3 mm margin well part target volume suspect microscopic tumor extension receive 2 Gy per fraction . Control intervention ( group B ) : 7 week standard radio-chemotherapy 5x2.0 Gy per week total dose 70 Gy 20 mg/m²/d Cisplatin week 1 5 . In group A B : The treatment elective cervical lymphatic area give session GTV single dose 1.6 Gy 56 Gy ( call simultaneous integrated boost concept ) .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Anoxia</mesh_term>
	<criteria>Signed write informed consent Age ≥ 18 ≤ 70 year Independent gender Independent race ECOG 0 2 Tumor oral cavity , oropharynx hypopharynx Histology : squamous cell carcinoma Curative treatment intend Tumor classify irresectable ( see Appendix ) Woman childbearing age : negative pregnancy test serum Contraception male female patient partner childbearing potential , willingness use effective contraceptive method study duration 2 month post therapy Sufficient bone marrow reserve 7 day study inclusion ; ( leukocytes ≥ 4 x 109/l , absolute . neutrophile ( ANC ) ≥ 2 x 109/ ; thrombocyte count ≥ 100 x 109/l ; Hemoglobin ≥ 10g/dl ) adequate liver function 7 day study inclusion ( total bilirubine ≤ 2,5 x ULN ( upper limit normal ) , ASAT/ ALAT ≤ 2,5 x ULN , alkaline phosphatase ≤ 2,5 x ULN institution 's normal value ) adequate kidney function 7 day study inclusion ; serum creatinine ≤ 130 μmol/l ; creatinine clearance ≥ 70 ml/min patient dental examination start therapy necessary treat , adaptation teeth protection bar percutane feed tube apply start treatment Infiltration mandible / larynx impair renal and/ liver function secondary malignancy , unknown primary cancer , nasopharynx cancer salivary gland cancer Metastatic disease Another cancer within 5 year study entry Serious concomitant disease medical condition Pregnancy lactation Women childbearing potential unclear contraception ( post menopausal woman must amenorrheal least 12 month consider nonchildbearing potential ) previous treatment chemotherapy , radiotherapy surgery head neck ( except excisional biopsy biopsy histology ) concurrent treatment experimental drug participation another clinical trial investigational drug within 30 day prior study screen life expectancy &lt; 12 month contraindication receive Cisplatin social situation limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>intensity modulate radiotherapy</keyword>
	<keyword>selective dose escalation</keyword>
	<keyword>hypoxia</keyword>
	<keyword>head cancer</keyword>
	<keyword>neck cancer</keyword>
</DOC>